SEC Form 4 · accession 0001209191-15-064734
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Craig Thompson
Officer — Chief Operating Officer
Period of report
Aug 5, 2015
Accepted (ET)
Aug 7, 2015 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 5, 2015 | M | 10,000 | $14.45 | A | 10,343 | D | |
| Common StockF1,F2 | Aug 5, 2015 | S | 10,000 | $46.31 | D | 343 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F3 | $14.45 | Aug 5, 2015 | M | 10,000 | D | — | Feb 2, 2024 | Common Stock | 10,000 | 167,501 | D |
Explanation of responses
- F1The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2015.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $44.92 to $47.60 per share. The reporting person herby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3This option vested as to 20% of the shares on February 3, 2014 and another 20% on February 3, 2015 and further vests as to 5% of the shares at the end of each successive three-month period thereafter until February 3, 2018.